V
RFK Jr. unilaterally gives the OK for some unapproved peptides.
Oh boy. This move refers to BPC-157, TB-500, Mots-C, KPV, epitalon, and semax. A document outlining the decision indicates that this seems to be the Health Secretary’s call, even though FDA scientists advised against it in July. This broadens access, but still requires a patient-specific prescription and adverse reporting.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
